Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho

Mizuho analyst Uy Ear raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $31.00 (from $26.00) while maintaining a Outperform rating.

The analyst commented, "We update our Sarepta model to incorporate 2026 guidance for product sales and operating expenses and raise our price target to $31 from $26, reiterating our Outperform rating. Our revisions assume steeper Exondys 51 erosion beginning in 2027 due to potential competition from Dyne’s (DYNE, not covered) z‑rostudirsen, but this is offset by our reinstatement of our full valuation for Amondys 45/Vyondys 53. Recent FDA developments suggest improving regulatory flexibility with rare-disease development going forward, which we believe significantly reduces the risk of these PMO products being withdrawn due to the negative Phase 3 ESSENCE trial. We also see potential upside to SRPT around the announcement of a new CEO, with leadership continuity critical as Sarepta navigates a demanding execution phase—rebuilding Elevidys demand, defending the PMO franchise, and advancing high‑impact regulatory and clinical milestones. Finally, our valuation excludes any contribution from SRP‑1003/SRP‑1001 in DM1/FSHD, representing unmodeled upside potential."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Medtronic, Inc. (MDT) PT Lowered to $101 at Needham
• Old Dominion Freight Line (ODFL) PT Raised to $233 at TD Cowen